October 19 (SeeNews) - Romanian state-controlled drug maker Antibiotice [BSE:ATB] said it won a tender held by the European Commission for providing the necessary stocks of antibiotics for the treatment of Covid-19 associated infections during the second wave of the pandemic.
Antibiotice Iasi will deliver 2.75 million vials of its product AmoxiPlus (amoxicillin/clavulanic acid in the form of sterile injectable powder) over a period of 12 months, at the request of European countries, it said in a press release on Friday.
According to the drug maker, winning the auction involved obtaining a maximum score by cumulatively meeting four essential conditions regarding quality, shelf life, price, speed and prompt delivery.
"Antibiotice provides Europe with a strategic product of the utmost importance for the treatment of COVID-19 associated infections. We won the auction with a common sense price, giving European countries accessibility to this product," Antibiotice Iasi CEO Ioan Nani said.
"However, beyond providing the necessary AmoxiPlus for European markets, deliveries will be made primarily to cover the need for anti-infective drugs for patients in Romania. We respect our contracts, ensuring the continuity of deliveries to our national partners."
Amoxicillin with clavulanic acid, along with piperacillin with tazobactam, are the main products recommended by the World Health Organization in anti-infective treatment, Antibiotice explained.
Antibiotice is the only pharmaceutical company in Romania that has a production flow for sterile injectable powders. Produced for over 30 years, this superior generation antibiotic is sold by Antibiotice in hospitals in Romania, Great Britain, Vietnam, Hungary, Lithuania, Iraq, Yemen.
In July 2020, Antibiotice announced that it has made its first deliveries of two injectable anti-infectives used in the treatment of infections associated with Covid-19 for hospitals in the UK and the US. Some 2.5 million vials will be delivered by the end of 2020, it said at the time.
Iasi-headquartered Antibiotice's shares traded 3.85% higher at 0.54 lei as at 1052 CET on Monday on the Bucharest Stock Exchange.
(1 euro=4.8737 lei)